



DURING TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS

# Signatera looks deeper

**Signatera is a personalized, tumor-informed assay that tracks ctDNA dynamics to evaluate response and optimize treatment**


Less than 20% of patients will derive sustained response or clinical benefit to ICIs.<sup>1</sup>

## Is the treatment working?

Use ctDNA for real-time assessment of immunotherapy response

A decrease in ctDNA relative to baseline at the beginning of cycle 3 is a strong predictor of PFS and OS.<sup>2</sup>

PFS among patients with both baseline and cycle 3 ctDNA values




## Is the tumor truly progressing?

Use ctDNA to clarify indeterminate radiologic findings, including pseudoprogression

ctDNA dynamics precedes clinical response assessed by CT scans.<sup>2</sup>

Patient with squamous cell carcinoma of the head and neck




## Is there a need to change or reinitiate treatment?

Identify exceptional responders with ctDNA clearance


Achieving ctDNA clearance at any time during treatment correlates with durable OS.<sup>2</sup>

OS was 100% with ctDNA clearance with at least one on-treatment timepoint




\*Median follow-up beyond first clearance of 25.4 months (range 10.8-29.5)





# Signatera reports are easy to interpret and help guide treatment decisions



## Ordering Altera and Signatera with one single tumor sample

Conserve tumor tissue by ordering Signatera for treatment monitoring together with Altera, a tumor profiling test to support therapy selection.

- Enablement of long-term monitoring
- One-stop-shop ordering for two tests
- Simpler logistics for patients
- All results available through physician portal
- Truly personalized care for your oncology patients

### Learn more about Signatera:

Tel: **+1.650.489.9050** | Email: **signateraquestions@natera.com** | Visit: **natera.com/oncology**

#### References

1. Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. *JAMA Network Open*. 2019;2(5):e192535-e192535. 2. Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. *Nat Cancer*. 2020;1:873-881. <https://doi.org/10.1038/s43018-020-0096-5>

13011 McCallen Pass, Building A Suite 100 | Austin, TX 787 | [www.natera.com](http://www.natera.com) | 1.650.489.9050 | Fax 1.650.412.1962

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2021 Natera, Inc. All Rights Reserved. 20210415\_NAT-8020468

